Pharmaceutical Companies

Amgen’s latest acquisition is centered on Dark Blue’s lead candidate, DBT 3757, which specifically treats acute myeloid leukemia that affects bone marrow and blood cells.

Sanofi will leverage Earendil’s artificial intelligence (AI)-powered drug discovery platform to support the design and development of multiple new therapeutic assets.

The collaboration aimed to support the distribution of Valneva’s single-dose vaccine, Ixchiq, in low- and middle-income countries (LMICs) across Asia.

Through this agreement, Sanofi will gain full ownership of Heplisav-B, a two-dose hepatitis B vaccine that received US approval in 2017 and European authorization in 2021.

Through this acquisition, J&J gains access to HLD-0915, a clinical-stage, once-daily oral therapy intended for the treatment of prostate cancer.

With this latest authorisation, individuals now have access to a long-acting option for prevention rather than daily pill-based regimens.

This deal gives Samsung Biologics its first manufacturing site in the US and reinforces its long-term commitment to serving the North American biopharmaceutical market.

The therapy is indicated for patients aged 12 years and older with severe asthma characterized by an eosinophilic phenotype.

This hub will enable closer collaboration with health authorities, clinicians, scientific associations, medical societies, and institutional partners throughout the Middle East and Africa.

The project will generate between 500 and 700 direct jobs and feature advanced digital infrastructure to ensure operational efficiency, traceability, and robust quality control.